Аутоиммунный анти-NMDA-энцефалит, ассоциированный с новой коронавирусной инфекцией COVID-19

В статье представлен клинический случай 19-летней пациентки с достоверным аутоиммунным анти-NMDА-энцефалитом на фоне перенесенной коронавирусной инфекции, который сопровождался в дебюте заболевания симптомами кататонии, эпилептическим синдромом и мутизмом. Этот случай дополняет статистику наблюдений данной патологии включением вируса SARS-CоV-2 в список возможных этиологических факторов. Проведен анализ симптомов кататонии, доминирующей в дебюте клинической картины заболевания.

1. Kolls B.J., O’Keefe Y.A., Sahgal A.K. Autoimmune Encephalitis: NMDA Receptor Encephalitis as an Example of Translational Neuroscience. Neurotherapeutics. 2020;17(2):404–413. https://doi.org/10.1007/s13311-020-00861-2

2. Dalmau J., Armangué T., Planagumà J., Radosevic M., Mannara F., Leypoldt F. et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. The Lancet Neurology. 2019;18(11):1045–1057. https://doi.org/10.1016/S1474-4422(19)30244-3

3. Schmitt S.E., Pargeon K., Frechette E.S., Hirsch L.J., Dalmau J., Friedman D. Extreme delta brush; A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094–1100. https://doi.org/10.1212/WNL.0b013e3182698cd8

4. Vitaliani R., Mason W., Ances B., Zwerdling T., Jiang Z., Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Annals of Neurology. 2005;58(4):594–604. https://doi.org/10.1002/ana.20614

5. Dalmau J., Tüzün E., Wu H., Masjuan J., Rossi J.E., Voloschin A. et al. Paraneoplastic anti–N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Annals of Neurology. 2007;61(1):25–36. https://doi.org/https://doi.org/10.1002/ana.21050

6. Armangue T., Leypoldt F., Dalmau, J. Autoimmune encephalitis as diff erential diagnosis of infectious encephalitis. Current Opinion in Neurology. 2014;27(3):361–368. https://doi.org/10.1097/WCO.0000000000000087

7. Huang Q., Xie Y., Hu Z., Tang X. Anti-N-methyl-D-aspartate receptor encephalitis: A review of pathogenic mechanisms, treatment, prognosis. Brain Research. 2020;1727(June2019):146549. https://doi.org/10.1016/j.brainres.2019.146549

8. Valencia Sanchez C., Theel E., Binnicker M., Toledano M., McKeon A. Autoimmune Encephalitis After SARS-CoV-2 Infection. Neurology. 2021;97(23):e2262 LP–e2268. https://doi.org/10.1212/WNL.0000000000012931

9. Хорева М.А., Серикова И.Ю., Смагина И.В., Голенко А.А., Смирнов К.В., Завьялов А.Е., Драганик И.А. Клинический случай энцефалита с антителами к NMDA-рецепторам на фоне новой коронавирусной инфекции (COVID-19). Российский неврологический журнал. 2022;27(1):106–112. [Khoreva M.A., Serikova I.Y., Smagina I.V., Golenko A.A., Smirnov K.V., Zavyalov A.E., Draganic I.A. Clinical case of anti-NMDA receptor encephalitis associated with new coronaviral infection (COVID-19). Russian neurological journal. 2022;27(1):106–112. (In Russ.)]. https://doi.org/10.30629/2658-7947-2022-27-1-106-112

10. Gouse B.M., Spears W.E., Nieves Archibald A., Montalvo C. Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism. Brain Behav Immun. 2020;89:529–530. https://doi.org/10.1016/j.bbi.2020.08.007

11. Vazquez-Guevara D., Badial-Ochoa S., Caceres-Rajo K.M., Rodriguez-Leyva I. Catatonic syndrome as the presentation of encephalitis in association with COVID-19. BMJ Case Rep. 2021;14(6):e240550. https://doi.org/10.1136/bcr-2020-240550

12. Fusunyan M., Praschan N., Fricchione G., Beach S. Akinetic Mutism and Coronavirus Disease 2019: A Narrative Review. J Acad Consult Liaison Psychiatry. 2021;62(6):625–633. https://doi.org/10.1016/j.jaclp.2021.08.009

13. Pollak T.A., Lennox B.R., Müller S., Benros M.E., Prüss H., Tebartz van Elst L. et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. The Lancet Psychiatry. 2020;7(1):93–108. https://doi.org/10.1016/S2215-0366(19)30290-1

14. Blum R.A., Tomlinson A.R., Jetté N., Kwon C.S., Easton A., Yeshokumar A. K. Assessment of long-term psychosocial outcomes in anti-NMDA receptor encephalitis. Epilepsy and Behavior. 2020;108:107088. https://doi.org/10.1016/j.yebeh.2020.107088

15. Al-Diwani A., Handel A., Townsend L., Pollak T., Leite M. I., Harrison P.J. et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. The Lancet Psychiatry. 2019;6(3):235–246. https://doi.org/10.1016/S2215-0366(19)30001-X

16. Graus F., Titulaer M.J., Balu R., Benseler S., Bien C. G., Cellucci T. et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology. 2016;15(4):391–404. https://doi.org/10.1016/S1474-4422(15)00401-9

17. Balu R., Mccracken L., Lancaster E., Graus F., Dalmau J., Titulaer M.J. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology. 2019;92(3):E244–E252. https://doi.org/10.1212/WNL.0000000000006783

18. Quinn T., Dawson J., Walters M. Dr John Rankin; His Life, Legacy and the 50th Anniversary of the Rankin Stroke Scale. Scottish Medical Journal. 2008;53(1):44–47. https://doi.org/10.1258/RSMSMJ.53.1.44

19. Bush G., Fink M., Petrides G., Dowling F., Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatrica Scandinavica. 1996;93(2);129–136. https://doi.org/https://doi.org/10.1111/j.1600-0447.1996.tb09814.x

20. Tandon R., Heckers S., Bustillo J., Barch D.M., Gaebel W., Gur R.E. et al. Catatonia in DSM-5. Schizophrenia Research. 2013;150(1):26–30. https://doi.org/10.1016/j.schres.2013.04.03

21. Fraune J., Gerlach S., Rentzsch K., Teegen B., Lederer S., Affeldt K. et al. Multiparametric serological testing in autoimmune encephalitis using computer-aided immunofl uorescence microscopy (CAIFM). Autoimmunity Reviews. 2016;15(10):937–942. https://doi.org/10.1016/j.autrev.2016.07.024

22. Titulaer M.J., McCracken L., Gabilondo I., Armangué T., Glaser C., Iizuka T. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet Neurology. 2013;12(2):157–165. https://doi.org/https://doi.org/10.1016/S1474-4422(12)70310-1

23. Planagumà J., Haselmann H., Mannara F., Petit-Pedrol M., Grünewald B., Aguilar E. et al. Ephrin-B2 prevents N-methylD-aspartate receptor antibody eff ects on memory and neuroplasticity. Annals of Neurology. 2016;80(3):388–400. https://doi.org/https://doi.org/10.1002/ana.24721

24. Takahashi Y., Nishimura S., Takao E., Kasai R., Enokida K., Ida K. et al. Characteristics of internalization of NMDA-type GluRs with antibodies to GluN1 and GluN2B. Journal of Neuroimmunology. 2020;349:577427. https://doi.org/10.1016/j.jneuroim.2020.577427

25. Sell J., Haselmann H., Hallermann S., Hust M., Geis C. Autoimmune encephalitis: novel therapeutic targets at the preclinical level. Expert Opinion on Therapeutic Targets. 2021;25(1):37–47. https://doi.org/10.1080/14728222.2021.1856370

26. Prüss H. Autoantibodies in neurological disease. Nature Reviews Immunology. 2021;21(12):798–813. https://doi.org/10.1038/s41577-021-00543-w

27. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. The Lancet Neurology. 2011;10(1):63–74. https://doi.org/https://doi.org/10.1016/S1474-4422(10)70253-2

28. Mann A.P., Grebenciucova E., Lukas R.V. Anti-N-methyl-Daspartate-receptor encephalitis: Diagnosis, optimal management, and challenges. Therapeutics and Clinical Risk Managemen. 2014;10(1):517–524. https://doi.org/10.2147/TCRM.S61967

29. Ciano-Petersen N.L., Cabezudo-García P., Muñiz-Castrillo S., Honnorat J., Serrano-Castro P.J., Oliver-Martos B. Current status of biomarkers in anti-n-methyl-d-aspartate receptor encephalitis. International Journal of Molecular Sciences. 2021;22(23):1–16. https://doi.org/10.3390/ijms222313127

30. Derksen S.J., Goraj B., Molenaar J.P., Van der Hoeven J.G. Severe anti NMDA encephalitis and EBV infection. Netherlandes Journal of Critical Care. 2013;17(5):19–21.

31. Solís N., Salazar L., Hasbun R. Anti-NMDA Receptor antibody encephalitis with concomitant detection of Varicella zoster virus. Journal of Clinical Virology. 2016;83:26–28. https://doi.org/10.1016/j.jcv.2016.08.292

32. Onpoaree N., Veeravigrom M., Sanpavat A., Suratannon N., Sintusek P. Unremitting diarrhoea in a girl diagnosed anti-Nmethyl-D-aspartate-receptor encephalitis: A case report. World Journal of Clinical Cases. 2020;8(20):4866–4875. https://doi.org/10.12998/wjcc.v8.i20.4866

33. Gable M.S., Gavali S., Radner A., Tilley D.H., Lee B., Dyner L. et al. Anti-NMDA receptor encephalitis: Report of ten cases and comparison with viral encephalitis. European Journal of Clinical Microbiology and Infectious Diseases. 2009;28(12):1421–1429. https://doi.org/10.1007/s10096-009-0799-0

34. Nóbrega P.R., Morais N.M. de M., Braga-Neto P., da Silva Barros L.S., Honório F.P.P., Dellavance A. et al. NMDAR Encephalitis Associated With Acute Chikungunya Virus Infection:A New Trigger? Frontiers in Pediatrics. 2020;8(April):8–11. https://doi.org/10.3389/fped.2020.00176

35. Martinez H.R., Olguin-Ramirez L.A., Camara-Lemarroy C.R. Lyme borreliosis as a trigger for NMDA receptor encephalitis? Neurological Sciences. 2018;39(10):1815–1817. https://doi.org/10.1007/s10072-018-3497-9

36. Predkele N., Mednieks J. Lyme disease and associated nmdar encephalitis: A case report and literature review. Neurology International. 2021;13(4):487–496. https://doi.org/10.3390/neurolint13040048

37. Salovin A., Glanzman J., Roslin K., Armangue T., Lynch D.R., Panzer J.A. Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection. Neurology: Neuroimmunology and NeuroIn fl ammation. 2018;5(4):4–9. https://doi.org/10.1212/NXI.0000000000000458

38. Kim T.J., Lee S.T., Moon J., Sunwoo J.S., Byun J.I., Lim J.A. et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Annals of Neurology. 2017;81(2):183–192. https://doi.org/10.1002/ana.24860

39. Shu Y., Guo J., Ma X., Yan Y., Wang Y., Chen C. et al. Anti-Nmethyl-D-aspartate receptor (NMDAR) encephalitis is associated with IRF7, BANK1 and TBX21 polymorphisms in two populations. European Journal of Neurology. 2021;28(2):595–601. https://doi.org/10.1111/ene.14596

40. Wenke N.K., Kreye J., Andrzejak E., van Casteren A., Leubner J., Murgueitio M.S. et al. N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit. Annals of Neurology. 2019;85(5):771–776. https://doi.org/10.1002/ana.25460

41. Ding Y., Yang C., Zhou Z., Peng Y., Chen J., Pan S. et al. Clinical signifi cance of soluble adhesion molecules in anti-NMDAR encephalitis patients. Annals of Clinical and Translational Neurology. 2019;6(5):945–953. https://doi.org/10.1002/acn3.740

42. Räuber S., Heming M., Repple J., Ruland T., Kuelby R., SchulteMecklenbeck A. et al. Cerebrospinal fl uid fl ow cytometry distinguishes psychosis spectrum disorders from diff erential diagnoses. Molecular Psychiatry. 2021;November:1–10. https://doi.org/10.1038/s41380-021-01244-5

43. Wilke J.B.H., Hindermann M., Berghoff S. A., Zihsler S., Arinrad S., Ronnenberg A. et al. Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis. Molecular Psychiatry. 2021;26:7746–7759. https://doi.org/10.1038/s41380-021-01238-3

44. Jurek B., Chayka M., Kreye J., Lang K., Kraus L., Fidzinski P. et al. Human gestational N-methyl-d-aspartate receptor autoantibodies impair neonatal murine brain function. Annals of Neurology. 2019;86(5):656–670. https://doi.org/10.1002/ana.25552

45. Pröbstel A.K., Zamvil S.S. Do maternal anti–N-methyl-D-aspartate receptor antibodies promote development of neuropsychiatric disease in children? Annals of Neurology. 2019;86(5):653–655. https://doi.org/10.1002/ana.25584

46. Gresa-Arribas N., Titulaer M. J., Torrents A., Aguilar E., McCracken L., Leypoldt F. et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. The Lancet Neurology. 2014;13(2):167–177.https://doi.org/https://doi.org/10.1016/S1474-4422(13)70282-5

47. Herken J., Prüss H. Red fl ags: Clinical signs for identifying autoimmune encephalitis in psychiatric patients. Frontiers in Psychiatry. 2017;8(FEB):1–9. https://doi.org/10.3389/fpsyt.2017.00025

48. Scott J.G., Gillis D., Swayne A., Blum S. Testing for antibodies to N-methyl-d-aspartate receptor and other neuronal cell surface antigens in patients with early psychosis. Australian and New Zealand Journal of Psychiatry. 2018;52(8):727–729. https://doi.org/10.1177/0004867418782421

49. Engen K., Wortinger L.A., Jorgensen K.N., Lundberg M., Bohman H., Smelror R.E. et al. Autoantibodies to the N-MethylD-Aspartate Receptor in Adolescents with Early Onset Psychosis and Healthy Controls. MedRxiv. 2020;01.06.20016626. https://doi.org/10.1101/2020.01.06.20016626

50. Warren N., Swayne A., Siskind D., O’gorman C., Prain K., Gillis D., Blum S. Serum and CSF anti-nmdar antibody testing in psychiatry. Journal of Neuropsychiatry and Clinical Neurosciences. 2020;32(2):154–160. https://doi.org/10.1176/appi.neuropsych.19030079

51. Warren N., Flavell J., O’Gorman , C., Swayne A., Blum S., Kisely S., Siskind D. Screening for anti-NMDAR encephalitis in psychiatry. Journal of Psychiatric Research. 2020;125(March):28–32. https://doi.org/10.1016/j.jpsychires.2020.03.007

52. Espinola-Nadurille M., Flores-Rivera J., Rivas-Alonso V., Vargas-Cañas S., Fricchione G.L., Bayliss L., et al. Catatonia in patients with anti-NMDA receptor encephalitis. Psychiatry and Clinical Neurosciences. 2019;73(9):574–580. https://doi.org/10.1111/pcn.12867

53. Marques Macedo I., Gama Marques J. Catatonia secondary to anti-N-methyl-D-aspartate receptor (NMDAr) encephalitis: a review. CNS Spectrums. 2019;1–18. https://doi.org/10.1017/s1092852919001573

54. DeSena A.D., Greenberg B.M., Graves D. Three Phenotypes of Anti–N-Methyl-d-Aspartate Receptor Antibody Encephalitis in Children: Prevalence of Symptoms and Prognosis. Pediatric Neurology. 2014;51(4):542–549. https://doi.org/https://doi.org/10.1016/j.pediatrneurol.2014.04.030

55. Ludwig R.J., Vanhoorelbeke K., Leypoldt F., Kaya Z., Bieber K., McLachlan S.M. et al. Mechanisms of autoantibody-induced pathology. Frontiers in Immunology. 2017;8(05). https://doi.org/10.3389/fi mmu.2017.00603

56. Day G.S., High S.M., Cot B., Tang-Wai D.F. Anti-NMDA-receptor encephalitis: case report and literature review of an underrecognized condition. Journal of General Internal Medicine. 2011;26(7):811–816. https://doi.org/10.1007/s11606-011-1641-9

57. Graus F., Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol. 2012;25(6):795–801. https://doi.org/ 10.1097/WCO.0b013e328359da15

58. Graus F., Vogrig A., Muñiz-Castrillo S., Antoine J. C. G., Desestret V., Dubey D. et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurology(R) Neuroimmunology & Neuroin fl ammation 2021;8(4):e1014. https://doi.org/10.1212/NXI.0000000000001014